The FDA has approved Bristol Myers Squibb's novel schizophrenia drug Cobenfy, offering a new treatment option by targeting cholinergic receptors instead of dopamine receptors. Clinical trials show effectiveness in relieving symptoms with fewer side effects, though warnings about potential adverse effects are included.